Turning Point Therapeutics Inc.

04/12/2021 | Press release | Distributed by Public on 04/12/2021 07:07

Turning Point Therapeutics Initiates Global Phase 1/2 Forge-1 Clinical Study of TPX-0131, a Next-Generation ALK Inhibitor